Jazz Pharmaceuticals Ireland Limited is an Irish operating subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a specialty biopharmaceutical company headquartered at Waterloo Exchange, Dublin 4, Ireland, with U.S. operations in Palo Alto, Carlsbad, Philadelphia and Durham. Jazz plc was incorporated in Ireland in 2005 as Azur Pharma and took its current name after the January 2012 merger with Jazz Pharmaceuticals, Inc. (founded 2003, California). Per its FY2025 Form 10-K it had approximately 2,890 employees worldwide and total revenues of $4.27 billion in 2025 (net loss $356 million). Reuters/GlobalData list market capitalization around $15 billion. Ownership is public; the Irish entity sits within the Jazz plc group.
The company develops and commercializes rare-disease medicines. Key products include the oxybate franchise Xywav and Xyrem (narcolepsy, idiopathic hypersomnia), Epidiolex/Epidyolex (cannabidiol for Lennox-Gastaut, Dravet and tuberous sclerosis complex epilepsies), and oncology/hematology drugs Zepzelca (lurbinectedin), Rylaze/Enrylaze, Defitelio, Vyxeos, Ziihera (zanidatamab) and Modeyso (dordaviprone). It also owns manufacturing sites in Athlone (Ireland), Kent (U.K.) and Villa Guardia (Italy).
Litigation posture: an operating company that litigates primarily as a brand plaintiff. Of 29 tracked cases, 20 are plaintiff suits — almost all Hatch-Waxman/ANDA infringement actions filed in the District of New Jersey (and Delaware) against generic filers including Lupin, Teva, Granules, Alkem, Tris Pharma, Amneal, Roxane, Wockhardt, Mallinckrodt and Ascent. The nine defendant appearances are defensive: the consolidated Xyrem antitrust MDL brought by purchasers (e.g., UFCW Local 1500 Welfare Fund), Avadel's Delaware counterclaims/antitrust and trade-secret suits, and three PTAB proceedings (Amneal, Ranbaxy, Par) in which six REMS patents were invalidated. Venues are New Jersey and Delaware, not the Eastern District of Texas.
Notable matters: the Avadel global settlement (October 2025) resolving mutual Delaware patent and antitrust claims, the resolved Xyrem antitrust MDL ($233.5 million charge in 2025), and the February 2026 Tris Pharma suits over Xyrem/Xywav referenced in the case list.